TABUTEAU HERRIOT

CIK 00012199271 companyNEW YORK, NY

SEC Profile

Transactions

Companies

Filings

CIK

0001219927

Recent Transactions

50 trades

Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2026-01-07−31,261→ 32,410 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2026-01-07$8.02/sh+31,261→ 38,490 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2026-01-07$170.38/sh−31,261→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2026-01-06$8.02/sh+29,450→ 36,679 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2026-01-06−29,450→ 63,671 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2026-01-06$172.33/sh−29,450→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2026-01-05−78,703→ 93,121 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2026-01-05$171.28/sh−78,703→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2026-01-05$8.02/sh+78,703→ 85,932 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-04$148.18/sh−10,558→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-04−10,558→ 171,824 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-04$8.02/sh+10,558→ 17,787 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-03−20,163→ 182,382 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-03$8.02/sh+20,163→ 27,392 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-03$146.94/sh−20,163→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-02$8.02/sh+49,252→ 56,481 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-12-02$144.59/sh−49,252→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-12-02−49,252→ 202,545 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-11-05$134.49/sh−21,775→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-11-05−21,775→ 251,797 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-11-05$8.02/sh+21,775→ 29,004 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-11-04−50,459→ 273,572 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-11-04$8.02/sh+50,459→ 57,688 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-11-04$133.79/sh−50,459→ 7,229 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-11-03$132.34/sh−91,705→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-11-03−91,705→ 324,031 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-11-03$8.02/sh+91,705→ 98,934 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-10-08−12,774→ 415,736 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-10-08$8.02/sh+12,774→ 20,003 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-10-08$118.84/sh−12,774→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-10-07−13,390→ 428,510 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-10-07$8.02/sh+13,390→ 20,619 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-10-07$118.77/sh−13,390→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-10-06$8.02/sh+19,220→ 26,449 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-10-06−19,220→ 441,900 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-10-06$120.17/sh−19,220→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-09-16−19,719→ 461,120 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-16$8.02/sh+19,719→ 26,948 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-16$114.19/sh−19,719→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-09-15−15,254→ 480,839 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-15$8.02/sh+15,254→ 22,483 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-15$117.37/sh−15,254→ 7,229 total
Sale
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-12$118.96/sh−27,907→ 7,229 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Common Stock
2025-09-12$8.02/sh+27,907→ 35,136 total
Exercise/Conversion
Axsome Therapeutics, Inc.$AXSM
Stock Option (Right to Buy)
2025-09-12−27,907→ 496,093 total
Award
Axsome Therapeutics, Inc.$AXSM
Performance Stock Units
2025-02-24+28,609→ 28,609 total
Award
Axsome Therapeutics, Inc.$AXSM
Employee Stock Option (Right to Buy)
2025-02-21+28,887→ 28,887 total
Award
Axsome Therapeutics, Inc.$AXSM
Restricted Stock Units
2025-02-21+28,609→ 28,609 total
Award
Axsome Therapeutics, Inc.$AXSM
Employee Stock Option (Right to Buy)
2024-02-27+87,192→ 87,192 total
Award
Axsome Therapeutics, Inc.$AXSM
Restricted Stock Units
2024-02-27+47,886→ 47,886 total

Companies

Axsome Therapeutics, Inc.
Director, Chief Executive Officer, 10% Owner
$AXSM

Recent Filings

Address

C/O AXSOME THERAPEUTICS, INC. ONE WORLD TRADE CENTER, 29TH FLOOR

NEW YORK, NY, 10007

View on SEC.gov